Matthew Oberley, Chief Clinical Officer at Caris Life Sciences, shared a post by Caris Life Sciences on LinkedIn:
“It was really impressive to see this project from the start through the SABCS unveiling.
In addition to ECOG-ACRIN and NSABP leaders and investigators, it was a team effort within Caris Life Sciences overseen by George Sledge, David Spetzler, and others including Ming Chen and his computational pathology team, and Daniel Magee and his data science team.
Congrats to all and I hope to see this improve the lives of patients with Breast Cancer with testing at Caris soon!”
Quoting Caris Life Sciences’s post:
“Today during SABCS 25, researchers presented the initial findings from a major multi-year collaboration between the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and Caris Life Sciences® (Caris) focused on transforming recurrence risk assessment in early-stage breast cancer through artificial intelligence (AI).
‘By integrating imaging, clinical data, and molecular profiling, we are advancing beyond single-dimension diagnostics to deliver a more precise and comprehensive understanding of recurrence risk in breast cancer’ said Caris EVP and Chief Medical Officer George W. Sledge.
More posts from SABCS 2025.